NCT05569018 Efficacy of a Transdiagnostic Group Treatment for Emotional Disorders Applied in Blended Format: a Controlled Study.
| NCT ID | NCT05569018 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitat Jaume I |
| Condition | Anxiety Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 144 participants |
| Start Date | 2024-11-23 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 144 participants in total. It began in 2024-11-23 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will consist in a randomized controlled clinical trial (RCT) to test the efficacy of a blended group transversal protocol (BLGr-TP) compared to a face-to-face group transversal protocol (FFGr-TP). The main aims of the study are the following: * To analyze the differential efficacy of the BLGr-TP versus the FFGr-TP for the treatment of emotional disorders in aspects of clinical measures, as well as in terms of retention and dropout rate and adherence. * To analyze the differential acceptability of the BLGr-TP versus the FFGr-TP for the treatment of emotional disorders. In addition, it is intended to carry out a study of mediators and moderators of the efficacy of both interventions. The established hypotheses in relation to the main goals are: * Both treatment modalities (FFGr-TP and BLGr-TP) will achieve improvements in the symptoms of emotional disorders, reflected in the scores of the clinical measures. * The BLGr-TP will show equivalent efficacy to the FFGr-TP. * The BLGr-TP will show an acceptability comparable to the face-to-face protocol. Both modalities will be well valued by the participants. * In both treatment modalities, the changes achieved are expected to be maintained over time (3, 6 and 12 months).
Eligibility Criteria
Inclusion Criteria: * Being 18 years old or more. * DSM-5 (APA, 1013) diagnostic criteria for emotional disorder (panic disorder, agoraphobia, social anxiety disorder, generalized anxiety disorder, major depressive disorder, dysthymia, obsessive-compulsive disorder, non-specified anxiety disorder, non-specified depressive disorder). * Good understanding of Spanish. * Access to the Internet and email address. * Informed consent to participate. Exclusion Criteria: * Diagnosis of a severe mental disorder (psychotic disorder, bipolar disorder, substance and/or alcohol dependence). * High risk of suicide. * Having a serious medical illness or other condition that prevents treatment from being carried out. * Receiving another psychological treatment during the study period. * Changes and/or increases in pharmacological treatment during the study period (a decrease is accepted).
Contact & Investigator
Amanda Díaz-García, Dr.
PRINCIPAL INVESTIGATOR
University of Zaragoza, Teruel Campus
Frequently Asked Questions
Who can join the NCT05569018 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Anxiety Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05569018 currently recruiting?
Yes, NCT05569018 is actively recruiting participants. Contact the research team at breton@uji.es for enrollment information.
Where is the NCT05569018 trial being conducted?
This trial is being conducted at Castellon, Spain.
Who is sponsoring the NCT05569018 clinical trial?
NCT05569018 is sponsored by Universitat Jaume I. The principal investigator is Amanda Díaz-García, Dr. at University of Zaragoza, Teruel Campus. The trial plans to enroll 144 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.